Transcript for Vaccine Watch: Johnson and Johnson moves forward in vaccine trials
Many believe that this pandemic crisis will end once a safe and effective vaccine is approval just Johnson just began stage four trials and their version is different than what's been tested so far. As our Bob Woodruff reports in this week's vaccine watch. Today Johnson & Johnson the largest pharmaceutical company in the US became the fourth company to launch a late stage faced three Covert nineteen vaccine trial. In the United States this trial. The biggest yet. You're going to run this. Globally in North America Latin America but also stood in Southern Africa. We did pay more for recruiting people in a very diverse set off people elderly younger people. But also mostly focused on people over the highest risk for our corporate to disease. And unlike his competitors Madieu Pfizer and AstraZeneca the Johnson & Johnson vaccine would likely be given in a single shot. Rather than multiple shots over several weeks what's different is that we will be able to study a single those cousin efficacious vaccine and start to that in 60000 people placebo controlled we showed in animal studies in preclinical studies about two months ago that a single shot of this vaccine was -- and Janet we visited doctor Dan Peru slab weeks ago where he showed us some of the early experiments demonstrating that a single shot might offer full protection. It's much more convenient to go to your pharmacy or your doctor and get our single shot essentially once and done rather than having to remember to call back. Three or four weeks later for a second shot at moving forward 60000. People across the globe will be given the shot in a phase three trial. Which is jointly funded by Johnson Johnson and the US government's operation warp speed. What we anticipate. We will spend it on the totality of this phase three trial. Will be just show what. Over half a billion dollars about 480 plus million dollars president trump is offered a rosy prediction of when a vaccine could be available. But Johnson & Johnson is months behind competitors like Pfizer in the journal. Advises doing really well identifies is doing really well. Johnson & Johnson as incredible vaccine there's really doing well that probably be a little bit later. Johnson & Johnson has cautiously said it could have an FDA green light by 2021. Whereas some of its competitors might be authorized as early as this year. But many Americans are concerned of the speed of vaccine development with a recent acts his poll showing six out of ten Americans. Wouldn't take the first one up. All the people involved AMOCO in nineteen vaccine effort to communicate very clearly with the public about. The attention to safety if this trial is successful Johnson and Johnson and said it will provide one billion doses of its vaccine each year. And since it'll likely take one shot rather than two the company says it could produce twice the number of doses as its competitors. This is Bob Woodruff tracking the race for a vaccine.
This transcript has been automatically generated and may not be 100% accurate.